Thermo Fisher Scientific SARS-CoV-2 Spike Protein (RBD) Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

2-5 µg/mL

View 1 publication 1 publication

Immunohistochemistry (Paraffin) (IHC (P))

0.5 µg/mL

-

Immunocytochemistry (ICC/IF)

20 µg/mL

-

ELISA (ELISA)

1 µg/mL

-

Product Specifications

Species Reactivity

Virus

Published species

Not Applicable

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Anti-SARS-CoV-2 (COVID-19) Spike RBD antibody was raised against a peptide corresponding to 19 amino acids near the carboxyterminus of SARS-CoV-2 (COVID-19) Spike glycoprotein RBD. The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19) Spike protein RBD.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS

Contains

0.02% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2890583

Target Information

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold symptoms to severe effects including death and respiratory distress. The CoV Spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Of note is the Spike protein receptor-binding domain (RBD, S-RBD) in SARS-CoV-2 Spike protein which binds strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibits significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD in comparison. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.